| target_debate_target | Should DISEASE-CAUSING (DISEASE-CAUSING Protein) be prioritized as a therapeutic | 0.43 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should DNAJB6 (DNAJB6 Protein) be prioritized as a therapeutic target for neurod | 0.39 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should ACSL4 (Long-chain-fatty-acid--CoA ligase 4) be prioritized as a therapeut | 0.49 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should PVALB (Parvalbumin) be prioritized as a therapeutic target for neurodegen | 0.33 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should PHB2 (PHB2 Protein) be prioritized as a therapeutic target for neurodegen | 0.41 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should TFEB (TFEB Protein) be prioritized as a therapeutic target for neurodegen | 0.43 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should RHOT1 (RHOT1 Protein) be prioritized as a therapeutic target for neurodeg | 0.40 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should C4B (C4B Protein) be prioritized as a therapeutic target for neurodegener | 0.44 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should DGAT1ANDSOAT1 (DGAT1ANDSOAT1) be prioritized as a therapeutic target for | 0.47 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should OCT4 (OCT4 Protein) be prioritized as a therapeutic target for neurodegen | 0.46 | 0 | 4 | completed | 2026-04-27 | |
| target_debate_target | Should TRAK1_KIF5A (Trafficking kinesin protein 1 / Kinesin family member 5A) be | 0.32 | 0 | 4 | completed | 2026-04-27 | |
| sess_test-hypothesis | Hypotheses created for system testing (hyp_test_* prefix) | 0.77 | 7 | 4 | completed | 2026-04-26 | test-hypothesis-fixtures-v1 |
| sess_legacy-pre-pipe | Hypotheses created before the analysis pipeline was established (pre-2026-04-01) | 0.81 | 7 | 4 | completed | 2026-04-26 | legacy-pre-pipeline-import-v1 |
| sess_SDA-2026-04-23- | The debate highlighted that G2019S shows elevated baseline RAB10 phosphorylation | 0.80 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-23-gap-debate-20260417-033119-54941818 |
| sess_SDA-2026-04-26- | How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen | 0.76 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260425-225305 |
| sess_SDA-2026-04-26- | Can retromer-stabilizing compounds like R55 prevent neurodegeneration in vivo? | 1.00 | 0 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-073255-6a58fb27 |
| sess_SDA-2026-04-26- | What is the minimum effective dose of trazodone required for disease-modifying e | 1.00 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-081101-dfe3eacb |
| sess_SDA-2026-04-26- | What is the optimal dosage and timing of melatonin administration for AD prevent | 1.00 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260411-090734-1be1b913 |
| sess_SDA-2026-04-26- | How does the intron-retained RNA isoform mechanistically reduce glucocerebrosida | 1.00 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260412-094853-199f4f1b |
| sess_SDA-2026-04-26- | Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ | 1.00 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260417-033134-20519caa |
| hyp-debate-664901bf- | Formal debate: TLR4 priming is the actionable driver in: How does gut microbiome | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260425-224724 |
| hyp-debate-664901bf- | Formal debate: age-linked CpG drift is the actionable driver in: Are DNA methyla | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260410-111542-7f40fe3e |
| hyp-debate-664901bf- | Formal debate: age-linked CpG drift is the actionable driver in: Are age-related | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260410-112902-5b3fc173 |
| hyp-debate-664901bf- | Formal debate: tight-junction remodeling is the actionable driver in: Blood-brai | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260426-001501 |
| hyp-debate-664901bf- | Formal debate: ubiquitylation-dependent turnover is the actionable driver in: Ho | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181402-259766ab |
| hyp-debate-664901bf- | Formal debate: plasma LPS-binding protein separates causal from compensatory sta | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260425-224724 |
| hyp-debate-664901bf- | Formal debate: ATAC-seq accessibility separates causal from compensatory states | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260410-111542-7f40fe3e |
| hyp-debate-664901bf- | Formal debate: ATAC-seq accessibility separates causal from compensatory states | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260410-112902-5b3fc173 |
| hyp-debate-664901bf- | Formal debate: plasma GFAP separates causal from compensatory states in: Blood-b | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260426-001501 |
| hyp-debate-664901bf- | Formal debate: K48/K63 ubiquitin chain balance separates causal from compensator | 0.75 | 0 | 3 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181402-259766ab |
| sess_SDA-2026-04-26- | What blood-brain barrier permeability changes serve as early biomarkers for neur | 1.00 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260426-001521 |
| sess_SDA-2026-04-26- | Does manipulating orexin-A directly rescue cognitive deficits and circadian dysf | 0.78 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-184240-f72e77ae |
| sess_SDA-2026-04-26- | What distinguishes seed-competent tau species from non-pathogenic tau during tra | 0.78 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260412-094623-bb7e1c4f |
| sess_SDA-2026-04-26- | What is the role of GPX4-dependent ferroptosis, lipid peroxidation, and iron han | 0.78 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-ferroptosis-mnd-768eaeba1be3 |
| sess_SDA-2026-04-26- | What blood-brain barrier permeability changes serve as early biomarkers for neur | 1.00 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260426-002803 |
| sess_SDA-2026-04-26- | What blood-brain barrier permeability changes serve as early biomarkers for neur | 1.00 | 7 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260426-011448-7c85f5dc |
| sess_SDA-2026-04-26- | How do ALS-linked UBQLN2 mutations affect its ubiquitylation-dependent stability | 0.78 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-pubmed-20260410-181402-259766ab |
| sess_SDA-2026-04-26- | Blood-brain barrier permeability changes as early biomarkers for neurodegenerati | 0.78 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260426-001501 |
| sess_SDA-2026-04-26- | Are age-related DNA methylation changes protective adaptations or pathological d | 0.78 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260410-112902-5b3fc173 |
| sess_SDA-2026-04-26- | Are DNA methylation changes in neurodegeneration causal drivers or protective co | 0.78 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-debate-20260410-111542-7f40fe3e |
| sess_SDA-2026-04-26- | How does gut microbiome dysbiosis contribute to neuroinflammation and neurodegen | 0.78 | 3 | 4 | completed | 2026-04-26 | SDA-2026-04-26-gap-20260425-224724 |
| sess_hypdebate_h_45d | Hypothesis debate: Multi-Biomarker Composite Index Surpassing Amyloid PET for Tr | 0.50 | 1 | 4 | completed | 2026-04-26 | SDA-2026-04-16-gap-pubmed-20260410-192526-f2bbb9ab |
| sess_hypdebate_h_cef | Hypothesis debate: Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-002 | 0.50 | 1 | 4 | completed | 2026-04-26 | |
| sess_hypdebate_h_cef | Hypothesis debate: Plasma p-tau217-Triggered Exosome Dosing Maximizes lncRNA-002 | 0.50 | 1 | 4 | completed | 2026-04-26 | |
| sess_hypdebate_h_0f0 | Hypothesis debate: PLCG2 Allosteric Modulation as a Precision Therapeutic for TR | 0.50 | 1 | 4 | completed | 2026-04-26 | SDA-2026-04-01-gap-001 |
| sess_hypdebate_h_0f0 | Hypothesis debate: PLCG2 Allosteric Modulation as a Precision Therapeutic for TR | 0.50 | 1 | 4 | completed | 2026-04-26 | SDA-2026-04-01-gap-001 |
| sess_hypdebate_h_var | Hypothesis debate: Closed-loop optogenetic targeting PV interneurons to restore | 0.50 | 1 | 4 | completed | 2026-04-26 | SDA-2026-04-03-26abc5e5f9f2 |
| sess_hypdebate_h_var | Hypothesis debate: Closed-loop transcranial focused ultrasound targeting EC-II S | 0.50 | 1 | 4 | completed | 2026-04-26 | SDA-2026-04-03-26abc5e5f9f2 |
| sess_hypdebate_h_611 | Hypothesis debate: TREM2-Dependent Microglial Senescence Transition | 0.64 | 1 | 4 | completed | 2026-04-26 | SDA-2026-04-26-trem2-showcase |
| sess_hypdebate_SDA_2 | Hypothesis debate: SASP Modulation Rather Than Cell Elimination | 0.50 | 1 | 4 | completed | 2026-04-26 | SDA-2026-04-04-gap-senescent-clearance-neuro |